JNJ vs PFE stock comparison
Johnson & Johnson vs. Pfizer · data as of November 13, 2026
Johnson & Johnson (JNJ) has a market value of about $687.9B, Pfizer (PFE) about $164.7B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Pfizer $63.6B.
On our five checks Johnson & Johnson scores higher: 2.6 out of 5 (average) against 2.2 (weak).
By area, the stronger company is Pfizer on value; Pfizer on future growth; Johnson & Johnson on track record; Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.
Pfizer is cheaper on earnings (P/E 41.3 vs. 43.4).
Johnson & Johnson leads on 12 of the compared lines and Pfizer on 12.
Side by side
| JNJ | PFE | |
|---|---|---|
| Size and price | ||
| Market cap | $687.9B | $164.7B |
| Share price | $285.75 | $28.89 |
| Score | ||
| Overall score (of 5) | 2.6 | 2.2 |
| Value | 0 | 1 |
| Future growth | 0 | 2 |
| Track record | 4 | 2 |
| Financial health | 4 | 2 |
| Shareholder returns | 5 | 4 |
| Valuation | ||
| P/E (TTM) | 43.4 | 41.3 |
| Forward P/E | 25.1 | 10.1 |
| Price / free cash flow | 33.4 | 14.0 |
| Price / sales | 6.9 | 2.6 |
| EV / EBITDA | 26.7 | 16.1 |
| PEG | 2.91 | — |
| DCF value vs. price | −39% | −31% |
| Business | ||
| Revenue | $99.3B | $63.6B |
| Net income | $16.1B | $4.0B |
| Free cash flow | $20.6B | $11.8B |
| Net margin | 16.2% | 6.3% |
| Gross margin (5-yr avg.) | 69.1% | 66.5% |
| ROIC (5-yr avg.) | 16.6% | 11.4% |
| Growth | ||
| Revenue growth (1 yr) | 6.0% | -1.7% |
| Revenue growth (5 yrs, per year) | 2.7% | 8.5% |
| EPS growth (5 yrs, per year) | 14.9% | -3.6% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$27.4B | -$51.7B |
| Dividend yield | 1.88% | 5.95% |
| Shareholder yield | 2.8% | 5.9% |
| Analysts | ||
| Upside to average target | −2% | +5% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, PFE TTM to September 27, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Johnson & Johnson or Pfizer?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Johnson & Johnson scores 2.6 out of 5 and Pfizer 2.2; the table shows where each one is stronger.
Is Johnson & Johnson cheaper than Pfizer?
On trailing earnings, Pfizer trades at a P/E of 41.3 and Johnson & Johnson at 43.4, so Pfizer is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Johnson & Johnson or Pfizer?
Over five years Pfizer grew revenue about 8.5% a year and Johnson & Johnson about 2.7% a year.
Which pays a higher dividend?
Johnson & Johnson yields 1.88% and Pfizer 5.95%.
Full Johnson & Johnson analysis → Full Pfizer analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.